遗传突变在ALS和FTD基因对行为和认知变化的差异影响:系统性审查和元分析
Ana Maria Jiménez-García1, Maria Eduarda Tortorella2, Agnes Lumi Nishimura2,3
1BRABE Group, Department of Medicine and Health Sciences, Faculty of Life and Natural Sciences, University of Nebrija, C/del Hostal, 28248 Madrid, Spain.
International journal of molecular sciences
|July 12, 2025
概括
肌缩侧面硬化 (ALS) 和前性痴呆 (FTD) 的遗传突变显示出不同的行为模式. 识别这些基因特异性资料可以指导为患者和家人提供个性化护理.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 临床神经学 临床神经学
背景情况:
- 肌缩侧面硬化症 (ALS) 和前性痴呆症 (FTD) 具有共同的遗传联系和临床重叠.
- 了解行为症状的遗传基础对于诊断和护理至关重要.
研究的目的:
- 系统地审查和分析关于ALS/FTD基因突变的研究.
- 识别与关键基因突变相关的特定行为特征.
主要方法:
- 97项研究的系统综述和元分析.
- 包括3212名患有ALS/FTD基因突变的患者.
- 对基因特异性行为模式的分析.
主要成果:
- 与精神病和侵略相关的C9orf72突变;SOD1突变对认知影响最小.
- PGRN突变与冷漠/幻觉相关;MAPT与失禁;CHMP2B与社会缺陷相关.
- FUS,TBK1,PSEN1/2突变显示出不同的行为和早期发病模式.
结论:
- 在ALS/FTD谱中存在基因特异性的行为特征.
- 根据遗传特征进行量身定制的护理策略可以改善患者的生活质量.
- 需要完善的指导方针,整合遗传行为数据,以便更好地支持患者和家人.
关键词:
在C9orf72seqq中使用.马普特 (MAPT) 是一个在PGRNN中使用.肌缩侧面硬化症 (ALS) 是一种疾病.行为症状 行为症状认知障碍是一种认知障碍.前性痴呆症 (FTD) 是一种前性痴呆.遗传突变 基因突变更多相关视频
相关概念视频
Human Genetics
732
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
732
Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673
Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263


